US Infectious Disease Drugs Market Analysis Report 2022 to 2030

US Infectious Disease Drugs Market Analysis

$ 3999

US Infectious Disease Drugs Market valued at $49.87 Bn in 2023, projected to reach $58.36 Bn by 2030 with a 2.27% CAGR. The market is expanding due to the prevalence of infectious diseases, improvements in drug development, and an aging population. The market is dominated by key players like AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Novartis AG, Pfizer Inc., and Lupin Pharmaceuticals.

ID: IN10USPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Aneri Parekh

Buy Now

US Infectious Disease Drugs Market Executive Summary

US Infectious Disease Drugs Market valued at $49.87 Bn in 2023, projected to reach $58.36 Bn by 2030 with a 2.27% CAGR.

Infectious disease drugs are used to treat infections brought on by bacteria, viruses, fungi, and parasites. From common illnesses like respiratory and urinary tract infections to more serious problems like HIV/ AIDS, TB, and hepatitis, these medications are essential for managing and preventing infectious diseases. Different infectious illnesses are treated with different medication classes. Antibiotics, antivirals, antifungals, antiparasitics, and antiretrovirals are such medications. Every antibiotic class targets distinct kinds of infections and functions differently.

Rising rates of infectious diseases, rising healthcare costs, and improvements in drug research technologies are fueling the US market’s continued growth. Pharmaceutical companies are investing heavily in research and development to bring new medicines to market in response to the persistent danger of antibiotic resistance and the emergence of infectious illnesses.

With significant expansion, the global market for infectious disease drugs reached $118.75 Bn in 2023. A spike in diagnostic rates and government campaigns to increase public knowledge of infectious illness management are both responsible for this growth. The market environment is changing, as seen by a discernible rise in generic competition. Moving forward, the key to long-term growth is overcoming affordability barriers and improving treatment access, particularly in developing countries. Resolving these issues will be essential to guarantee that patients everywhere receive timely and sufficient care, which will spur additional industry innovations and developments.

Hepatitis C (HCV), HIV, and other infectious diseases are AbbVie's primary areas of focus in the US. They are working on several antiviral and antibacterial initiatives, including next-generation antibiotics for serious infections. Additionally, they take part in pro bono initiatives, investing funds in the study of remedies for illnesses that are often ignored, such as malaria, Chagas disease, and river blindness.

US infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Prevalence of Infectious Diseases: One major factor driving the market is the persistence of infectious disease prevalence in the US population. There is a constant need for infectious disease medications due to conditions like HIV/ AIDS, hepatitis, tuberculosis, influenza, and new infectious diseases. 25.2 Mn cases of flu were seen in the US in 2022.

Improvements in Drug Development: Constant research and development work results in the creation of novel drugs against infectious illnesses. Progress in fields like as genomics, molecular biology, and immunology is driving the market.

Aging Population: Due to weakening immune systems and comorbidities, the aging population is more vulnerable to infectious diseases. Drugs to treat infectious are in high demand as the population ages.

Market Restraints:

Regulatory Obstacles: Rigid FDA regulations can cause delays in drug approval, which can affect a company's ability to enter the market.

High Research and Development Costs: The significant R&D costs associated with developing new medications deter investment, particularly for conditions with little commercial potential.

Generic Competition: When a patent expires, other competitors enter the market, taking market share away and driving down prices.

Healthcare Policies and Regulatory Landscape

The regulatory body in charge of overseeing pharmaceuticals in the US is the Food and Drug Administration (FDA). The FDA ensures that new drugs are safe and effective by evaluating and approving them. Pre-clinical, clinical, and FDA review are the three primary phases of the development process for most new therapeutic drugs and biologics. The process of obtaining a license for a pharmaceutical involves several difficulties, including stringent rules, costly and time-consuming development schedules, and difficulties with clinical trials.

Competitive Landscape

Key Players:

AbbVie Inc.
Gilead Sciences
GlaxoSmithKline plc
Merck & Co.
F. Hoffman-La Roche Ltd.
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Novartis AG
Pfizer Inc.
Lupin Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.